Main results
We identified four potential studies, of which three were excluded.
The included trial reported clinical pregnancy rates but not live births. There was no evidence of a difference in clinical pregnancy rate between those receiving an amoxycillin and clavulanic acid antibiotic combination (64/178: 36%) and those not (61/172: 35.5%) (OR1.02, 95% CI 0.66 to 1.58). Genital tract colonisation was significantly reduced in women receiving this antibiotic regimen (OR 0.59, 95% CI 0.37 to 0.95).
Authors' conclusions
This review suggests that the administration of amoxycillin and clavulanic acid prior to embryo transfer reduced upper genital tract microbial contamination but did not alter clinical pregnancy rates. The effect of this intervention on live birth is unknown. There are no data from randomised controlled trials to support or refute other antibiotic regimens in this setting.
Future research is warranted to assess the efficacy of alternative antibiotic regimens. Researchers should assess live birth as the primary outcome and address quantitative microbial colonization as a secondary outcome.
P L A I N L A N G U A G E S U M M A R Y

Antibiotics prior to embryo transfer in ART
In vitro fertilisation (IVF) describes an assisted reproductive technology (ART) during which a woman undergoes ovarian stimulation, surgical retrieval of eggs, fertilisation of eggs outside of the body, and finally the transfer of resulting embryo(s) into the uterus by an embryo transfer (ET) procedure. During an ET, the embryo(s) is passed through the cervix by means of a catheter. Many variables affect the chance of pregnancy after ET, including embryo quality, uterine factors and the embryo transfer technique. High levels of bacteria and other organisms in the upper genital tract have a detrimental effect on pregnancy rate after ET. Administration of antibiotics prior to ET may reduce the growth of these organisms and improve the outcomes of IVF. This review considered the question of whether antibiotics given at any time prior to ET affect pregnancy rates and other important outcomes of IVF.
In the only study which addressed this question, the use of an amoxycillin and clavulanic acid antibiotic regimen had no effect on clinical pregnancy rate despite demonstrating a reduction in upper genital tract colonisation. The effect on live birth rate is unknown.
The findings of this review do not support the use of an amoxycillin and clavulanic acid antibiotic regimen prior to ET for the purposes of improving IVF success. The effect of alternative antibiotic regimens on IVF outcomes is unknown and needs further research.
S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Antibiotics prior to embryo transfer in ART 
B A C K G R O U N D Description of the condition
In vitro fertilisation (IVF) is a form of assisted reproductive technology (ART) during which an egg is fertilised by sperm outside of the female reproductive tract and the resulting embryo placed in the uterus. The process of IVF involves controlled ovarian stimulation, egg retrieval, fertilisation by either combining eggs and sperm or intracytoplasmic sperm injection (ICSI), and embryo transfer (ET). During ET, a catheter is inserted via the cervical canal to deliver one or more embryos into the uterus. ET is a critical step in the ART cycle. While many women will reach the stage of ET with embryos of adequate quality, few of these embryos will implant and even fewer will achieve a live birth. 
Description of the intervention
This systematic review considered the effect of any antibiotic given by any route prior to ET, where the primary purpose of this intervention was to increase IVF success rates.
How the intervention might work
The association between increased cervico-vaginal microbial growth and reduced pregnancy rates after ET may indicate that the passage of the ET catheter is responsible for the introduction of microbes into the endometrial cavity. This upper genital tract infection or contamination may have a negative impact on implantation and IVF success rates by both endometrial and embryonic mechanisms (Moore 2000; Paulson 1990; Spandorfer 2001) . In the event of organisms stimulating an endometrial inflammatory response, pro-inflammatory cytokines may negatively alter the ability of an embryo to successfully implant (Spandorfer 2001) . Additionally, with the loss of the protective zona pellucida prior to implantation, the embryo is potentially exposed to nearby 
Why it is important to do this review
Embryo transfer (ET) has become the subject of much interest in recent years as practitioners seek to improve relatively poor implantation rates (Mains 2010 
O B J E C T I V E S
To evaluate the effectiveness and safety of antibiotic administration prior to ET during ART cycles.
M E T H O D S
Criteria for considering studies for this review
Types of studies
This review considered all published and unpublished randomised controlled trials (RCTs) which assessed the use of antibiotics prior to or at the time of embryo transfer in IVF cycles. The trials must have addressed at least one of the review's outcome measures to be included, however any studies identified as part of the systematic review that did not address the primary outcome criteria were assessed for pertinent summary statistics that should be included as part of the analysis. Quasi-randomised studies were not considered.
Types of participants
Women of any age undergoing fresh or frozen embryo transfer (ET) as part of an IVF or IVF and ICSI cycle for infertility of any cause.
Types of interventions
Trials comparing the use of antibiotic(s) prior to ET with any other antibiotic(s), placebo, or no intervention were eligible for inclusion.
Types of outcome measures Primary outcomes
Live birth rate or ongoing pregnancy (beyond 20 completed weeks gestation) per woman randomised.
Secondary outcomes
1. Clinical pregnancy rate per woman randomised (identification of a fetal heart on ultrasound at ≥ 7 weeks gestation). 2. Miscarriage rate (at < 20 completed weeks gestation or weighing < 500 g), as confirmed by ultrasound and pregnancy test or histology) per woman randomised (including partial loss of multiple pregnancies). 3. Ectopic pregnancy rate per woman randomised. 4. Multiple pregnancy rate per clinical pregnancy, confirmed by ultrasound or delivery. 5. Fetal abnormalities (as determined by fetal anatomy scan or after delivery) per woman randomised. 6. Adverse events associated with antibiotic administration and ET per woman randomised; adverse events included pain and adverse drug reactions such as hypersensitivity reactions, anaphylaxis, and gastrointestinal side effects (nausea, vomiting, diarrhoea). 7. Genital tract colonization rate, as defined by the study authors. 8. Pelvic infection, as defined by the study authors but including presentation post-ET with lower abdominal pain and one or more of fevers; abnormal cervico-vaginal discharge; raised C-reactive protein (CRP), erythrocyte sedimentation ratio (ESR) or white cell count (WCC).
Search methods for identification of studies
All published and unpublished RCTs of antibiotic use prior to ET were sought using the following search strategy, without any language restriction and in consultation with the Menstrual Disorders and Subfertility Group (MDSG) Trials Search Co-ordinator.
Electronic searches
The following electronic databases, trial registers and websites were searched (from inception to 02 February 2011 • Citation indexes (http://scientific.thomson.com/products/ sci/);
• conference abstracts on the ISI Web of Knowledge (http:// isiwebofknowledge.com/);
• LILACS database as a source of trials from the Portuguese and Spanish speaking world (http://bases.bireme.br/cgi-bin/ wxislind.exe/iah/online/?IsisScript=iah/iah.xis&base=LILACS& lang=i&form=F);
• ClinicalStudyResults for clinical trial results of marketed pharmaceuticals (www.clinicalstudyresults.org/);
• PubMed (www.ncbi.nlm.nih.gov/pubmed/), the random control filters for PubMed were taken from Chapter 6 of The Cochrane Handbook for Systematic Reviews of Interventions;
• OpenSIGLE database (http://opensigle.inist.fr/) for grey Literature from Europe;
• herbal or complimentary therapy protocols and reviews (at least one Chinese database was searched).
Searching other resources
The reference lists of articles retrieved by the search were handsearched and personal contact was made with experts in the field to obtain any additional data, when required. Any relevant journal and conference abstracts that were not covered in the MDSG register were handsearched in liaison with the Trials Search Coordinator. No additional relevant material was identified.
Data collection and analysis
Data collection and analysis was conducted in accordance with the Cochrane Handbook for Systematic Reviews of Interventions (Higgins 2011).
Selection of studies
The titles and abstracts of articles identified by the search were screened independently by one review author (BK); and those that were clearly irrelevant were removed. Articles were sourced if they appeared to be eligible for inclusion in the review based on the title and abstract. Two review authors (BK and AY) then independently examined the full text articles for suitability for inclusion in the review. Review authors corresponded with study authors to clarify study eligibility. Disagreements with regards to study eligibility were resolved by consensus.
Data extraction and management
Two authors (AY and BK) independently extracted data using a custom-designed data extraction form. Where studies had multiple publications, the main trial report was used as the reference and additional details supplemented by secondary papers. Review authors corresponded with study investigators in order to resolve any data queries, as required. One author (EF) entered the data into RevMan, which was checked by all authors against the data extraction forms to ensure against data entry errors.
Assessment of risk of bias in included studies
The included study was assessed for bias using the Cochrane risk of bias assessment tool (see Appendix 6) to assess: sequence generation, allocation concealment; blinding of participants, providers and outcome assessors; completeness of outcome data; selective outcome reporting; and any other sources of bias. Individual study authors were contacted to complete missing data. If no response was received, authors were followed up by a repeat email. Two authors (BK and AY) assessed the risk of bias, with any disagreements resolved by consensus or by discussion with a third author (RH).
Measures of treatment effect
Statistical analysis was performed in accordance with the guidelines for statistical analysis (Higgins 2011).
Unit of analysis issues
The primary analysis was per woman randomised. Multiple live births (for example twins or triplets) were counted as one live birth event.
In future reviews, where data are reported that does not allow valid analysis (for example 'per cycle' rather than 'per woman', where women contribute more than one cycle), the data will be summarised in an additional table and not subject to meta-analysis. Where applicable, a secondary analysis will be performed on such data where only a small proportion of multiple cycles have occurred.
Dealing with missing data
Attempts were made to obtain missing data from the original investigators, by contacting authors at the correspondence address provided and failing that by an e-mail to their last recorded address identified by an internet search. Only the available data were analysed. In future reviews, where data are unavailable an imputation of individual values will be undertaken for the primary outcomes only. Live births will be assumed not to have occurred in participants with unreported outcomes. Any imputation undertaken will be subject to sensitivity analysis (see below).
Assessment of heterogeneity
As only one study met the inclusion criteria, an assessment of heterogeneity was not required. In future updates of this review, the authors will consider whether the clinical and methodological characteristics of included studies were sufficiently similar for meta-analysis to provide a meaningful summary. Statistical heterogeneity will be assessed by the I 2 statistic, where necessary. An I 2 value > 50% will be taken to indicate substantial heterogeneity (Higgins 2011). If substantial heterogeneity is detected, possible explanations will be explored in the sensitivity analysis.
Assessment of reporting biases
In view of the difficulty in detecting and correcting for publication bias and other reporting biases, the authors aimed to minimise their potential impact by ensuring a comprehensive search for eligible studies and by being alert for duplication of data. Because only one study was identified, a funnel plot was not required. For updates of this review, if 10 or more studies are analysed a funnel plot will be used to explore the possibility of small study effects (a tendency for estimates of the intervention effect to be more beneficial in smaller studies). Care was taken to search for 'within study' reporting bias, such as the failure to report obvious outcomes or reporting them in insufficient detail to allow inclusion. The primary outcome of live birth was not reported by the single study included in this review. In future updates, where identified studies fail to report the primary outcome of live birth, but do report interim outcomes such as pregnancy, assessment will be undertaken to assess whether those reporting the primary outcomes have typical values of the interim outcomes. The conclusions are presented in the 'Risk of bias' table. No reporting bias was detected. If reporting bias is found in future updates of this review, it will be incorporated in to the interpretation of review findings by means of a sensitivity analysis.
Data synthesis
The review protocol was to combine data from primary studies using fixed-effect models in the following comparisons:
1. a single antibiotic or an antibiotic combination versus placebo or no treatment; 2. a single antibiotic or an antibiotic combination versus another antibiotic or antibiotic combination. For each comparison, data synthesis was to be stratified by antibiotic dosage regimen (a single dose or course of multiple doses) and mode of antibiotic administration (either oral, topical or intravenous). An increase in the odds of an outcome measure, be that beneficial (for example live birth) or detrimental (for example miscarriage), is displayed graphically in the meta-analyses to the right of the centre-line. If there is a decrease in the odds of an outcomes, this will appear on the graph to the left of the centre-line.
Subgroup analysis and investigation of heterogeneity
The review protocol was to analyse the evidence for differences between the following subgroups.
1. A single antibiotic versus placebo or no treatment. 2. A single antibiotic versus another antibiotic.
3. An antibiotic combination versus placebo or no treatment.
4. An antibiotic combination versus another antibiotic(s). Further subgroup analysis was to be performed within the following groups: age, body mass index (BMI), IVF or ICSI, fresh and frozen ETs, luteal phase support prior to ET, pre-implantation genetic diagnosis (PGD), and patients receiving antibiotics because of risk factors for pelvic infection (such as endometriomas, hydrosalpinges, multiple punctures at egg pick up). Subgroup analysis was also to be undertaken by date of study publication (prior to and after 2000) to account for changes in practice that may have occurred over time. In the setting of heterogeneity exceeding 50%, subgroup analysis was to be performed to explain the findings. No subgroup analysis was possible for the current review.
Sensitivity analysis
Sensitivity analyses were to be conducted for the primary outcome to determine whether the conclusions were robust to arbitrary decisions made regarding the eligibility of studies and analysis. These analyses were to include consideration of whether conclusions would have differed if: 1. eligibility was restricted to studies without high risk of bias; 2. alternative imputation strategies had been adopted. No sensitivity analysis was required.
R E S U L T S Description of studies
See Characteristics of included studies; Characteristics of excluded studies.
Results of the search
Our search strategy identified four potentially relevant studies (Brook 2006; Karimzadeh 2000; Peikrishvili 2004; Primi 2004) . Three were excluded from analysis, one because it was an abstract of an oral conference presentation and, at the time of publication, the author was unable to provide any data for inclusion (Karimzadeh 2000) . The study by Peikrishvilli (Peikrishvili 2004) was excluded on the basis of a pseudo-random treatment allocation and the third because of co-intervention (Primi 2004).
Included studies
Brook 2006 reported a randomised controlled trial of antibiotic prophylaxis in 350 patients attending an English IVF clinic who underwent a transvaginal oocyte retrieval and ET as part of IVF or ICSI with or without PGD treatment. Patients were randomly allocated to 1.5 g of co-amoxyclav tablets (750 mg the night before ET and 750 mg 2 hours prior to ET) or no treatment. Outcome measures were the bacterial contamination rate of ET catheters and clinical pregnancy rate.
Excluded studies
Peikrishvili 2004 reported a pseudo-randomised controlled trial of antibiotic prophylaxis in women undergoing ET as part of an ART cycle. While this paper addressed intervention and outcome measures relevant to this review, the method of randomisation (based on year of birth) made it inadequate for inclusion. Karimzadeh 2000 appeared in the literature only as a conference abstract. The author was contacted and was unable to provide data at the time of publication of the review. Primi 2004 assessed both the benefits of laser assisted hatching and the use of combined antibiotic and immunosuppressive therapy associated with this technology. As methylprednisolone was used as co-treatment with antibiotics, this paper was excluded from further analysis.
Risk of bias in included studies
For further risk of bias information refer to Figure 1 .
Figure 1. Risk of bias summary Allocation
Brook 2006 used computer generated randomisation with randomisation codes placed in sealed opaque envelopes. A third party not involved in the trial produced the randomisation codes and sealed the envelopes. There was no evidence of allocation bias in this study.
Blinding
The embryologist performing the ET and the microbiologist who assessed bacterial growth were blinded to treatment Brook 2006. The clinician performing the oocyte collection was aware of treatment allocation. It is unclear whether the clinician performing the ET was blinded. It is unclear whether this would have a significant impact on outcomes.
Incomplete outcome data
In Brook 2006 all randomised patients were assessed for the outcome of clinical pregnancy but bacteriological catheter analysis was only performed on 284 of the 350 women randomised. In the antibiotic arm 154/178 (86.5%) were analysed. The reasons for failure to analyse were: 12 catheters were discarded in error, 10 patients had failed fertilisation, 2 patients had failed cleavage. In the control arm 130/172 (75.6%) were analysed. The reasons for failure to analyse were: 26 catheters were discarded in error, 12 patients had failed fertilisation, 4 patients had failed cleavage. The authors reported that 215 women who presented for oocyte collection and ET during the time period of recruitment were ineligible for randomisation because they received antibiotic prophylaxis at the time of oocyte collection. The indications for this were a history of pelvic infection, endometriosis, hydrosalpinges or multiple ovarian punctures at the time of oocyte collection.
Selective reporting
There was no evidence of selective reporting.
Other potential sources of bias
No other potential sources of bias were identified.
Effects of interventions
See: Summary of findings for the main comparison
Comparison 1: antibiotics versus no treatment prior to embryo transfer (ET)
A single trial addressed the question of whether antibiotics given prior to ET improved IVF success (Brook 2006) . This trial investigated the use of 1.5 g of co-amoxyclav tablets (750 mg the night before ET and 750 mg 2 hours prior to ET).
Primary outcome -live birth rate
This outcome was not reported.
Secondary outcomes
Clinical pregnancy rate
There was no difference in clinical pregnancy rate between those receiving an amoxycillin and clavulanic acid antibiotic combination (64/178: 36%) and those not (61/172: 35.5%) (OR 1.02, 95% CI 0.66 to 1.58) (Analysis 1.1, Figure 2) . 
Ectopic pregnancy rate
Not reported.
Multiple pregnancy rate
Fetal abnormalities
Adverse events
Genital tract colonisation
Genital tract colonisation was significantly more likely in women who did not receive antibiotics prior to ET (81/130) compared to those that did (76/154) (OR 0.59, 95% CI 0.37 to 0.95). See Analysis 2.1, Figure 3 . 
D I S C U S S I O N Summary of main results
There is limited evidence from a single randomised controlled trial which addressed the question of whether antibiotics prior to embryo transfer (ET) improve IVF success rates. The reported study found no evidence of an improvement in clinical pregnancy rate despite identifying a reduction in genital tract colonization in women receiving antibiotics prior to ET. The effect on live birth rate is unknown (Summary of findings for the main comparison).
Overall completeness and applicability of evidence
The available study suggests that antibiotic administration prior to ET has no effect on IVF success. The combination of amoxycillin and clavulanate, when given in the regimen trialled, does not affect clinical pregnancy rates. The gold standard outcome measure in studies assessing fertility outcomes is live birth rates, however these data are not reported. In the absence of live birth data it is impossible to infer the influence of this antibiotic regimen on this outcome. Outcome data on rates of clinical pelvic infection and fetal anomalies, two outcomes of particular interest when discussing administration of pre-conception antibiotics, are not available. The impact of an alternative antibiotic regimen has also not been addressed. It is unfortunate that more high quality evidence from RCTs is not available. A study by Peikrishvili 2004 is the only other publication addressing the clinical question of this review, however substandard methodological quality made it ineligible for inclusion in a metaanalysis. Participants were pseudo-randomised based on odd or even year of birth and it is unclear whether they were recruited more than once. Additionally, it is unclear whether investigators or assessors were blinded to treatment allocation, and patient flow and attrition were not reported. This study reported on 275 women attending a single unit as part of an IVF or ICSI cycle. Patients received either amoxycillin 1000 mg + 125 mg clavulanic acid per day from day of egg pick up, for six days, or no treatment. As found by Brook 2006, the clinical pregnancy rate did not differ between those who received antibiotics (43/130: 31.1%) and the control group (48/145: 31.1%). Miscarriage rate was no different in those receiving antibiotics (11/43: 25.6%) compared to those who were not (16/48: 33.3%). Adverse effects only occurred in the antibiotic group and were nausea (10/130), diarrhoea (12/130) and vaginitis (15/130). The association between microbial colonization of the genital tract at the time of ET and poorer IVF outcomes is reasonably well established. In addition to assessing the effect of antibiotics on IVF outcomes, Brook 2006 also reported pregnancy rates relative to the degree of bacterial contamination of ET catheters (irrespective of antibiotic prophylaxis). Catheters that showed no growth were associated with a pregnancy rate of 47.2%, compared with 15.8% in the group whose catheter had a semi-confluent growth of gram positive bacteria (P < 0.05). This finding concurs with multiple prior studies which reported poorer pregnancy rates in the setting of increased endocervical microbial colonization at the time of ET (Egbase 1999; Fanchin 1998; Moore 2000; Salim 2002) . Despite this, a reduction in colonising bacteria through the use of antibiotic prophylaxis prior to ET, as demonstrated by Brook 2006, does not correlate with improved outcomes. Accepting an impact on success rates by genital tract bacterial colonization, the reason for a lack of impact of antibiotic prophylaxis is unclear. It may be that the degree of microbial eradication needs to be greater for there to be a relevant clinical effect. Alternatively, the antibiotic regimen may need to target different bacterial subgroups. It may also be the case that the antibiotic itself could be having a detrimental effect on IVF success.
Quality of the evidence
Brook 2006 was methodologically sound overall. There was failure to blind the clinician performing oocyte collection, possibly the clinician performing ET, and the patient, however it is unclear whether this would have introduced significant bias. There was no attrition for the outcome of clinical pregnancy, but not all patients randomised were assessed for the major outcome measure of catheter bacterial contamination. In the antibiotic arm 154/178 (86.5%) were analysed, while in the control arm 130/172 (75.6%) were analysed. The reasons for failure to analyse were similar in both groups apart from the number of catheters discarded in error, which was more than double in the intervention group (26 versus 12). Finally, it is worth noting that the population in the Brook 2006 study may have introduced bias as 215/775 (27.7%) of women who underwent transvaginal oocyte retrieval during the recruitment period were deemed ineligible for trial inclusion because they were 'at risk' for pelvic infection. These women received routine antibiotic prophylaxis at the time of oocyte collection. Outcomes were not described for this group. The indications for antibiotic prophylaxis were a history of pelvic infection, endometriosis, hydrosalpinges or multiple ovarian punctures at the time of oocyte collection. Not all IVF units would routinely administer antibiotic prophylaxis to this subgroup of women. It is plausible that including this 'at risk' subgroup could alter the study findings.
Potential biases in the review process
There were no identified biases in the review process.
Agreements and disagreements with other studies or reviews
There were no previous reviews identified.
A U T H O R S ' C O N C L U S I O N S
Implications for practice
This review suggests that, based on the limited available evidence, antibiotic prophylaxis with an amoxycillin and clavulanic acid combination reduces upper genital tract microbial contamination but there is no evidence that it improves clinical pregnancy rate. The effect of this intervention on live birth is unknown. There are no randomised controlled data to support or refute the use of other antibiotic regimens in this setting. More studies of sound methodological quality are required, particularly addressing the outcome of live birth.
Implications for research
Future research is warranted to assess the efficacy of alternative antibiotic regimens. Researchers should aim to assess live birth as a primary outcome and specifically address quantitative microbial colonization rates.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Brook
Methods
Randomised 
A P P E N D I C E S Appendix 1. Menstrual Disorders and Subfertility Specialised Register search strategy
Menstrual Disorders and Subfertility Database search strategy for EN1382 02.02.2011 Keywords CONTAINS "IVF" or "in vitro fertilisation" or "in vitro fertilization" or "*Embryo Transfer" or "ET" or "blastocyst transfer" or "ICSI" or "intracytoplasmic sperm injection" or Title CONTAINS"IVF" or "in vitro fertilisation" or "in vitro fertilization" or "*Embryo Transfer" or "ET" or "blastocyst transfer" or "ICSI" or "intracytoplasmic sperm injection" AND Keywords CONTAINS "antibiotics" or "amoxicillin" or "Amoxicillin-Clavulanic Acid" or "ampicillin" or "ceftezole" or "*Ceftizoxime" or "Ceftriaxone" or "Cefuroxime" or "Azithromycin" or "co-amoxiclav" or"Augmentin" or "cephalosporin" or "Cephalosporins" or "doxycycline" or "erythromycin" or "Metronidazole" or "tetracycline" or Title CONTAINS "antibiotics" or "amoxicillin" or "Amoxicillin-Clavulanic Acid" or "ampicillin" or "ceftezole" or "*Ceftizoxime" or "Ceftriaxone" or "Cefuroxime" or "Azithromycin" or "co-amoxiclav" or"Augmentin" or "cephalosporin" or "Cephalosporins" or "doxycycline" or "erythromycin" or "Metronidazole" or "tetracycline"
